BIMZELX Patent Gets Official FDA Time Stamp
Published Date: 1/27/2026
Notice
Summary
The FDA has officially set the review period for BIMZELX, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to keep exclusive rights, which can impact when generic versions hit the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until March 30 or July 27, 2026, to speak up.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in